Relay Therapeutics financials
$18.36+3.79%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $15.4M | $10.0M | $25.5M | $1.4M | $3.0M | $82.7M |
| Gross profit | $15.4M | $10.0M | $25.5M | $1.4M | $3.0M | $82.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$302.7M | -$372.5M | -$373.0M | -$299.3M | -$352.8M | -$55.8M |
| Net income | -$276.5M | -$337.7M | -$342.0M | -$290.5M | -$363.9M | -$230.2M |
| Net margin | −1800.6% | −3374.7% | −1338.7% | −21036.1% | −12012.9% | −278.5% |
| Diluted EPS | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 | $-5.40 |
| EBITDA | -$299.2M | -$367.0M | -$367.7M | -$295.1M | -$346.1M | -$52.2M |
| Operating cash flow | -$235.5M | -$249.1M | -$300.3M | -$229.5M | -$86.3M | -$102.5M |
| Free cash flow | -$235.9M | -$251.1M | -$304.4M | -$238.6M | -$89.7M | -$104.4M |
| Diluted shares | 171.6M | 142.9M | 122.6M | 112.2M | 95.1M | 42.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $84.0M | $124.3M | $143.7M | $151.8M | $280.1M | $447.6M |
| Short-term investments | $470.5M | $657.0M | $606.4M | $847.1M | $678.0M | $230.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $621.3M | $871.3M | $844.0M | $1.10B | $1.01B | $799.8M |
| Total liabilities | $54.3M | $93.5M | $92.0M | $149.6M | $110.6M | $36.5M |
| Shareholders' equity | $567.1M | $777.8M | $752.0M | $950.2M | $897.8M | $763.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology